Abstract
Preclinical evaluation of a 0.5 M solution of the manganese(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetate complex (Mn-DCTA, Cyclomang) has been carried out with a view to substitution of potentially toxic gadolinium-containing paramagnetic contrast agents for clinical MRI routines. The toxicological tests of Mn(II)-DCTA were performed on mice and rats. Liquid phantoms were used for evaluating the relaxivity of Mn(II)-DCTA in comparison to that of Gd(III)-DTPA and Mn-DTPA. The diagnostic imaging properties of Mn(II)-DCTA were quantitatively assessed on dogs with cerebral meningeomas (n = 10). The LD50 upon single administration in rats was above 17 ml/kg, thus slightly exceeding the corresponding values for of Gd(III)-DTPA and Mn-DTPA. The relaxivity of Mn(II)-DCTA amounted to R1 =3.68 (mM-1 · s-1) and did not differ significantly from the values known for Gd-DTPA and Mn-DTPA. Mn(II)-DCTA ensured high-intensity contrast of tumor areas in brain of dogs. It is concluded that Mn(II)-DCTA can be employed as a paramagnetic contrast agent in routine MRI studies and is worth further clinical evaluation.
| Original language | English |
|---|---|
| Pages (from-to) | 32-38 |
| Number of pages | 7 |
| Journal | Eksperimental'naya i Klinicheskaya Farmakologiya |
| Volume | 76 |
| Issue number | 10 |
| Publication status | Published - 1 Jan 2013 |
Fingerprint
Keywords
- Manganeses(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′- tetraacetate (Mn-DCTA)
- MRI
- Paramagnetic enhancement
- Preclinical evaluation
ASJC Scopus subject areas
- Toxicology
- Pharmacology
Cite this
Evaluation of manganese -trans-1,2-diaminocyclohexane-N,N,N′, N′-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging. / Usov, V. Yu; Belyanin, M. L.; Bezlepkin, A. I.; Churin, A. A.; Dubskaya, T. Yu; Vetoshkina, T. L.; Filimonov, V. D.
In: Eksperimental'naya i Klinicheskaya Farmakologiya, Vol. 76, No. 10, 01.01.2013, p. 32-38.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Evaluation of manganese -trans-1,2-diaminocyclohexane-N,N,N′, N′-tetraacetate complex (Cyclomang) as paramagnetic contrast agent for magnetic resonance imaging
AU - Usov, V. Yu
AU - Belyanin, M. L.
AU - Bezlepkin, A. I.
AU - Churin, A. A.
AU - Dubskaya, T. Yu
AU - Vetoshkina, T. L.
AU - Filimonov, V. D.
PY - 2013/1/1
Y1 - 2013/1/1
N2 - Preclinical evaluation of a 0.5 M solution of the manganese(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetate complex (Mn-DCTA, Cyclomang) has been carried out with a view to substitution of potentially toxic gadolinium-containing paramagnetic contrast agents for clinical MRI routines. The toxicological tests of Mn(II)-DCTA were performed on mice and rats. Liquid phantoms were used for evaluating the relaxivity of Mn(II)-DCTA in comparison to that of Gd(III)-DTPA and Mn-DTPA. The diagnostic imaging properties of Mn(II)-DCTA were quantitatively assessed on dogs with cerebral meningeomas (n = 10). The LD50 upon single administration in rats was above 17 ml/kg, thus slightly exceeding the corresponding values for of Gd(III)-DTPA and Mn-DTPA. The relaxivity of Mn(II)-DCTA amounted to R1 =3.68 (mM-1 · s-1) and did not differ significantly from the values known for Gd-DTPA and Mn-DTPA. Mn(II)-DCTA ensured high-intensity contrast of tumor areas in brain of dogs. It is concluded that Mn(II)-DCTA can be employed as a paramagnetic contrast agent in routine MRI studies and is worth further clinical evaluation.
AB - Preclinical evaluation of a 0.5 M solution of the manganese(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′-tetraacetate complex (Mn-DCTA, Cyclomang) has been carried out with a view to substitution of potentially toxic gadolinium-containing paramagnetic contrast agents for clinical MRI routines. The toxicological tests of Mn(II)-DCTA were performed on mice and rats. Liquid phantoms were used for evaluating the relaxivity of Mn(II)-DCTA in comparison to that of Gd(III)-DTPA and Mn-DTPA. The diagnostic imaging properties of Mn(II)-DCTA were quantitatively assessed on dogs with cerebral meningeomas (n = 10). The LD50 upon single administration in rats was above 17 ml/kg, thus slightly exceeding the corresponding values for of Gd(III)-DTPA and Mn-DTPA. The relaxivity of Mn(II)-DCTA amounted to R1 =3.68 (mM-1 · s-1) and did not differ significantly from the values known for Gd-DTPA and Mn-DTPA. Mn(II)-DCTA ensured high-intensity contrast of tumor areas in brain of dogs. It is concluded that Mn(II)-DCTA can be employed as a paramagnetic contrast agent in routine MRI studies and is worth further clinical evaluation.
KW - Manganeses(II) - trans-1,2-diaminocyclohexane-N,N,N′,N′- tetraacetate (Mn-DCTA)
KW - MRI
KW - Paramagnetic enhancement
KW - Preclinical evaluation
UR - http://www.scopus.com/inward/record.url?scp=84897019095&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897019095&partnerID=8YFLogxK
M3 - Article
VL - 76
SP - 32
EP - 38
JO - Eksperimental'naya i Klinicheskaya Farmakologiya
JF - Eksperimental'naya i Klinicheskaya Farmakologiya
SN - 0869-2092
IS - 10
ER -